Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Limited has issued a business update presentation dated 18 March 2026, outlining information intended solely for general informational purposes and not as investment advice. The company stresses that various aspects of its work remain under investigation, may change or be discontinued, and that no guarantees are made regarding the accuracy or completeness of the information provided.
The release emphasises that Rhythm, along with its directors and advisers, accepts no liability for any reliance placed on the material, and that the document does not constitute an offer or solicitation to buy or sell shares in any jurisdiction. It also underscores that forward-looking statements are inherently uncertain, subject to risks and assumptions beyond the company’s control, and should not be relied upon as indicators of future performance.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Limited operates in the healthcare and biotechnology sector, focusing on the development of diagnostic technologies. The company targets medical markets that rely on accurate, research-driven tools, positioning itself as an innovator in bioscience-based solutions for clinical and commercial applications.
Average Trading Volume: 950,004
Technical Sentiment Signal: Buy
Current Market Cap: A$72.76M
Learn more about RHY stock on TipRanks’ Stock Analysis page.